MG
IMDX

Michael Gelband’s Insight Molecular Diagnostics IMDX Stock Holding History

Michael Gelband’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.8K Buy
+14,029
New +$69.2K ﹤0.01% 1469
2019
Q2 		– Sell
-515
Closed -$41K – 1266
2019
Q1 		$41K Buy
+515
New +$33.2K ﹤0.01% 645

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Michael Gelband's IMDX Position: Q2 2026 in Review

Michael Gelband opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 14,029 shares worth $82.8K. The stake represents ﹤0.01% of the portfolio and ranks #1469 among its holdings. This is a return to the name: Michael Gelband previously reported a position in IMDX as recently as Q1 2019.

Michael Gelband first reported a position in IMDX in Q1 2019 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Michael Gelband held 14,029 shares of Insight Molecular Diagnostics worth $82.8K as of Q2 2026.
  • Insight Molecular Diagnostics was a new Michael Gelband position in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1469 holding.
  • Michael Gelband first reported a position in Insight Molecular Diagnostics in Q1 2019 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.